Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could early palliative care reduce aggressive End-of-Life cancer treatments?

NCT ID NCT07490106

Symptom relief Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly assigned to either early integrated palliative care or usual care. The goal is to see if early collaboration between oncologists and palliative care doctors leads to less chemotherapy, fewer ER visits, and fewer ICU stays near death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
early integrated palliative care
What this could lead to
If successful, this could show that early palliative care helps patients with advanced cancer avoid harsh treatments at the end of life.
What could go wrong
This is an early-stage study (not yet recruiting) that measures care patterns, not survival. Results may not apply to all cancer types or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 493 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged 18 years and older; * Diagnosed with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer; * Currently undergoing systemic palliative treatment (no prospect of cure); * Hospitalized on an unscheduled basis (i.e., unplanned hospitalization for scheduled oncology treatments); * Patient covered by the French social security system; * Informed consent, written and signed. Exclusion Criteria: * PS (WHO) = 4; * Patient receiving end-of-life care; * Patient opposed to the use of medical data for research purposes; * Person deprived of liberty or under guardianship; * Inability to undergo medical monitoring for the trial for geographical, social, or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm female reproductive organ cancer head and neck cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Digestive cancers Ent cancer Gynaecologic cancer Metastatic cancer or locally advanced Sarcoma metastatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Oscar Lambret

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.